OKUR
NASDAQ HealthcareOnKure Therapeutics, Inc. - Class A Common Stock
Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
�� 市场数据
| 价格 | $5.00 |
|---|---|
| 成交量 | 299,095 |
| 市值 | 68.37M |
| RSI（14日） | 74.5 超买 |
| 200日均线 | $2.95 |
| 50日均线 | $3.51 |
| 52周最高 | $5.06 |
| 52周最低 | $1.70 |
| Forward P/E | -2.43 |
| Price / Book | 1.22 |
🎯 投资策略评分
OKUR 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (56/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 OKUR in your text
粘贴任何文章、记录或帖子 — 工具将提取 OKUR 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.